Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Swedish Orphan Biovitrum ABSWOBY -6.00%67 Equity-to-Asset is 0.51 as of Jun. 2026, which is 2% above its 10-year median of 0.50. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $18.40 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 65.34% on this metric.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Equity-to-Asset or its related term are showing as below:
SWOBY'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37 Med: 0.5 Max: 0.65
Current: 0.51
During the past 13 years, the highest Equity to Asset Ratio of Swedish Orphan Biovitrum AB was 0.65. The lowest was 0.37. And the median was 0.50.
SWOBY's Equity-to-Asset is ranked worse than 65.34% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs SWOBY: 0.51
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Swedish Orphan Biovitrum AB Equity-to-Asset Related Terms
Swedish Orphan Biovitrum AB Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Equity-to-Asset falls into.
Swedish Orphan Biovitrum AB Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Swedish Orphan Biovitrum AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a Equity-to-Asset of 0.51 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is near median its historical median of 0.50. Over the past decade, Swedish Orphan Biovitrum AB's Equity-to-Asset has ranged from 0.37 to 0.65. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #658 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 65.3%.
Is Swedish Orphan Biovitrum AB's Equity-to-Asset too high?
Swedish Orphan Biovitrum AB's current Equity-to-Asset of 0.51 is near median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 0.65. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Swedish Orphan Biovitrum AB's value of 0.51 is 16.4% below this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #658 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #658 out of 1007 companies for Equity-to-Asset. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Swedish Orphan Biovitrum AB's value of 0.51 is 16.4% below this benchmark. Historically, Swedish Orphan Biovitrum AB's own Equity-to-Asset has ranged from 0.37 to 0.65 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.61, Swedish Orphan Biovitrum AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Equity-to-Asset of 0.51 is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Equity-to-Asset is 0.51, which is near median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Modestly Overvalued. The stock's GF Value™ is $18.40, compared to a current price of $23.50 — trading 27.7% above its estimated fair value. The current Equity-to-Asset is 0.51, which is near median its 10-year median of 0.50 and 16.4% below the Drug Manufacturers industry median of 0.61. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Equity-to-Asset is 0.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.50 is trading 27.7% above its estimated GF Value™ of $18.40.
GuruFocus considers Swedish Orphan Biovitrum AB to be Modestly Overvalued.
Key valuation signals for SWOBY:
Equity-to-Asset: 0.51 (near median its 10-year median of 0.50)
GF Value™: $18.40 vs. price of $23.50 (27.7% above fair value)
Industry Position: 16.4% below the Drug Manufacturers median (#658 of 1007)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
